« Back
Home /
Cediranib

Cediranib

Item no.	HY-10205-100mg
Manufacturer	MedChem Express
CASRN	288383-20-0
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Development Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer Uterine, Ovarian & Cervical Cancer
Type	Inhibitors
Specific against	other
Purity	99.87
Citations	[1]Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 2005, 65(10), 4389-4400.\|[2]Zhang L, et al. Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Sci Signal. 2015 Dec 8;8(406):ra125. Biomaterials. 2018 Apr;161:164-178. \|Biomed Res Int. 2021 Mar 30.\|Cell Stem Cell. 2019 Sep 5;25(3):373-387.e9.\|Discov Oncol. 2024 Nov 19;15(1):678.\|Eur J Pharmacol. 2023 Dec 27:176278.\|Harvard Medical School LINCS LIBRARY\|J Med Chem. 2023 Dec 13.\|Neuro Oncol. 2016 Apr;18(4):538-48. \|Sci Signal. 2015 Dec 8;8(406):ra125. \|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Life Sci. 2024 Jun 23:122862.
Smiles	FC1=C(OC2=C(C(C=C3OCCCN4CCCC4)=NC=N2)C=C3OC)C=CC5=C1C=C(C)N5
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AZD2171
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Autophagy; PDGFR; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	450.51
Product Description	Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 20 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; Protein Tyrosine Kinase/RTK
Isoform	PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10205-100mg-safety-datasheet.pdf